BioTrinity is the leading European Biopartnering and Investment Conference. It provides the best opportunity to meet investors, senior licensing executives from global pharma organisations and senior management of innovative drug development and platform technology companies.
Now in its 9th year, the de facto national biopartnering conference is expected once again to attract 1000+ delegates from over 30 countries. The new, dedicated MediTrinity stream will attract key personnel from medtech corporates and diagnostics R&D companies.
At the heart of the event are the world class speaker programme, compelling panels of experts and the powerhouse partnering system. Together with the unequalled networking opportunities for emerging companies to pitch for partners and investment, BioTrinity has become the best catalyst for business for R&D, pharma and medtech corporates:
In 2014 we hosted 2,462 one-to-one meetings over two days between 1,014 delegates from 32 countries, representing more than 624 companies.
Last year licensing contacts from large corporates included AbbVie, Amgen, Astellas, AstraZeneca, Boehringer, Bristol-Myers Squibb, Chiesi, Eli Lilly, Genzyme, GE, GlaxoSmithKline, Johnson & Johnson, Life Technologies, Linde AG, MSD, Novartis, Novo Nordisk, Sanofi-Aventis, Sanofi-Pasteur, Shire, Pfizer, Roche, Takeda as well as mid-sized including Vertex, Ferrer, Actelion, MorphoSys, Nordic Pharma, Norgine, Qiagen, QuantuMDx, and other senior BD&L executives.
Over 100 delegates from active VC and Corporate Venture firms included MedImmune Ventures, SR One, Johnson & Johnson Development Corporation, AbbVie Inc, Mitsui & Co, MPH Ventures, Norgine Ventures, Novartis Venture Fund, MS Ventures, MRL Venture Fund, Takeda Ventures, Unilever Ventures, Boehringer Ingelheim Ventures, Inventages, as well as Lundbeckfond Ventures, Novo A/S, Syncona, Index, Sofinnova, EdRIP and many international VCs.
Thanks to EBD Group's partneringONE®, the industry gold-standard partnering system with entirely private partnering:
You need to upgrade your Flash Player
The "Event of the Year" - BioTrinity 2014:
Huge partnering potential with global pharma / investors
100 presentations by hand-picked R&D companies
Innovative "Connect for Growth" zones that encouraged informal and formal collaborative interactions
Great networking opportunities with 1000 delegates
First class venue at Novotel London West
Exciting Social Programme:
The Big London Networking Party, BioTrinity Welcome Reception and Connect for Drinks
Europe's Largest Investor-only Dinner